Quince Therapeutics is a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform the lives of patients suffering from debilitating and rare diseases. The company is actively seeking compelling clinical-stage assets available for in-licensing and acquisition to expand our development pipeline.
Advancing innovative therapeutics that transform patients’ lives
Our pipeline includes a bone-targeting drug platform and precision bone growth molecule NOV004 which is available for out-licensing. NOV004 is an anabolic peptide engineered to precisely target and concentrate at the bone fracture site, resulting in rapid increases in bone density, strength, and expedited healing as demonstrated in extensive preclinical studies.